---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-22-000004"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2022-01-05T23:59:59+00:00"
generated_at: "2026-06-27T20:43:55.327387+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics announces leadership changes: Rencher retires, Beck and Fletcher appointed

## Summary
- Bill Rencher, Ph.D., retired as Head of CMC effective Jan 1, 2022; transitions to advisory role at $8,000/month through Apr 2022.
- Christopher Beck appointed SVP, Operations; previously VP of Program Management at Galera Therapeutics.
- Mark Fletcher, Ph.D., appointed VP, R&D; previously VP of Product Development at Pharmaceutical Associates, Inc.
- Appointments aim to advance lead candidate onapristone extended release (ONA-XR) in breast, ovarian, and endometrial cancers.
- Rencher's retirement was planned, not due to disagreement; advisory role continues through October 2022.

## SEC filing metadata
- accession: 0001842952-22-000004
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2022-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295222000004/0001842952-22-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295222000004/cntx-20220101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-22-000004
- JSON: https://secwatch.observer/filing/0001842952-22-000004.json
- Plain text: https://secwatch.observer/filing/0001842952-22-000004.txt

## Key facts
- Executive change
  Bill Rencher retired as Head of Chemistry Manufacturing Controls at Context Therapeutics Inc..
  - Action: retired
  - Role: Head of Chemistry Manufacturing Controls
  source text: As of January 1, 2022, Bill Rencher, Ph.D., retired as Head of Chemistry Manufacturing Controls of Context Therapeutics Inc. (the “Company”), and transitioned into an advisory role with the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842952/000184295222000004/0001842952-22-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.